Considering particular EMT/CSC molecular actors, studies, for instance, have detected CD44, often in conjunction with other canonical EMT markers, in CTCs isolated from many cancer types, which was associated with poor clinical outcomes in some studies [50,100,170,187,188,335,355,356]. This evidence concerns the gene CD44 and cancer.